热门资讯> 正文

埃夫里公司GAAP每股收益-8.07美元，收入1000万美元

2025-12-12 05:15

Evommune, Inc.(EVMN) 0

Evommune, Inc. press release (EVMN): Q3 GAAP EPS of -$8.07.
Revenue of $10M.
As of September 30, 2025, the Company had cash, cash equivalents and investments of $76.0 million, compared to $72.0 million as of December 31, 2024.

More on Evommune, Inc.

Evommune Aims For IPO In Bifurcated Biopharma Market
Evommune and BillionToOne climb on trading debut
Evommune and BillionToOne set IPO prices
Seeking Alpha’s Quant Rating on Evommune, Inc.
Historical earnings data for Evommune, Inc.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。